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Scenario
Mr X – a fit and healthy 30-year-old man – joins a group climbing 
Mount Kilimanjaro, hoping to reach Uhuru Peak (5 895 m above 
mean sea level). His 6-day, 5-night expedition is following the Rongai 
route, approaching from the northern side of Kilimanjaro. After 
flying in from his home at sea level in South Africa (SA), they begin 
their trek near the Kenyan border at 1 900 m. Despite no previous 
experience at altitude, he shows no signs of struggling with the ascent, 
and easily copes during the deliberately slow hikes of the first 3 days 
to reach Kikelewa Caves (3 675 m). However, on arrival at Mawenzi 
Tarn camp (4 300 m) at the end of the hot 4th day, Mr X complains 
of a headache, dizziness and nausea.
The local lead guide offers Mr X 800 mg oral ibuprofen to ease the 
headache and encourages him to rest. Having no appetite, Mr X skips 
dinner that night, but does take care to remain well hydrated. In the 
morning his headache has resolved, but he complains of having had 
fitful sleep. Routine screening by the guides shows elevated resting 
breathing and heart rates (respiratory rate 28/min.; heart rate 120/
min.). A portable fingertip pulse oximeter shows that his peripheral 
arterial oxygen saturation (SpO2) has dropped to 64%. The guides are 
nevertheless anxious to push on, and Mr X continues with the group 
to Kibo Huts (4 714 m).
During the day, his headache returns, and he feels lethargic 
and breathless. Nonetheless, with his bucket-list goal in sight, he 
participates in the final summit preparations. The group leaves camp 
for the summit at midnight. During the relentless climb to the crater 
rim (5 680 m), Mr X feels increasingly cold, and develops ataxia 
and tunnel vision. Amid the tired party in the predawn light, his 
deterioration remains unnoticed. At Gilman’s Point on the summit 
ridge, the group stops for a brief rest. Mr X is disorientated, has lost 
fine motor control, and speaks incoherently before he collapses.
By this point, the guides have discovered that you are a doctor, 
and turn to you for help. What is your assessment and action plan? 
Thinking back, if you were the expedition’s doctor, would you have 
intervened earlier?
Background
Although SA is not traditionally associated with high-altitude 
climbing, the country is blessed with many beautiful mountain 
ranges. An increasingly substantial proportion of the population 
takes part in recreational climbing and mountaineering, both locally 
and abroad. Many also travel to high-altitude regions worldwide 
for simple tourism, business or religious pilgrimages.[1] Globally, 
it has been estimated that >35 million people travel to altitudes of 
greater than 3 000 m per annum.[2] In southern Africa, several large 
metropolitan areas are above 1 500 m, and peaks of up to 3 482 m 
are regularly ascended. Despite this, there is generally a poor level of 
recognition of the implications and risks of high altitude for healthy 
travel and recreation among SA doctors.[3]
High altitude is defined as greater than 1 500 m above sea level. 
At this level, the physiological implications of decreasing ambient 
pressure (hypobaria) and corresponding decrease in the partial 
pressure of oxygen (hypoxia) are regularly apparent, although they do 
not have pathological consequences in healthy individuals. Altitude 
between 1 500 m  and 3 500 m is referred to by some authors as inter-
mediate, and it is within this range that altitude-related illnesses begin 
to manifest. Very high altitude is defined as being above 3 500 m, where 
simple physiological compensation is no longer sufficient to maintain 
oxygenation, and gradual acclimatisation is required. Exposure to 
extreme altitudes (above 5 500 m) without acclimatisation is highly 
likely to cause severe illness. The summit of Kilimanjaro (5 895 m) 
has an ambient pressure of approximately 47 kPa (less than half of 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Acute high-altitude illness
R Hofmeyr,1,2 MB ChB, DipPEC, DA, MMed (Anaes), FCA, FAWM; G Tölken,2,3 MA, STB; 
R De Decker,4 MSc, MB ChB, DCH (UK), FCPaeds (SA), Cert Med Genetics (Paeds)
1 Department of Anaesthesia and Perioperative Medicine, Faculty of Health Sciences, University of Cape Town, South Africa 
2 WildMedix, Cape Town, South Africa 
3 Mountain Rescue, Hottentots-Holland Section – Mountain Club of South Africa, Cape Town, South Africa  
4  Department of Paediatrics and Child Health, University of Cape Town and Red Cross War Memorial Children’s Hospital, Cape Town,  
South Africa
Corresponding author: R Hofmeyr (ross.hofmeyr@uct.ac.za)
A substantial proportion of South Africa (SA)’s population lives at high altitude (>1 500 m), and many travel to very high altitudes (>3 500 m) 
for tourism, business, recreation or religious pilgrimages every year. Despite this, knowledge of acute altitude illnesses is poor among SA doc-
tors. At altitude, the decreasing ambient pressure proportionally decreases available oxygen (hypobaric hypoxia). This triggers both imme-
diate respiratory compensation and gradual acclimatisation that occurs over days to weeks. Rapid ascents to altitudes above 2 500 m can 
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and HACE are diagnosed clinically. The Lake Louise Score questionnaire is used to elicit symptoms of AMS, and can be supplemented by 
assessing clinical signs such as tachycardia, tachypnoea, crepitations or ronchi, and ataxia. The mainstay of treatment for all but mild AMS 
is rapid descent to lower altitudes, which can be facilitated by administration of oxygen and drugs, including acetazolamide, dexamethasone 
and nifedipine, or use of a portable hyperbaric chamber.
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sea-level pressure), resulting in arterial oxygen tension (PaO2) of only 
6 kPa, even with ideal acclimatisation (Fig. 1). Blood gases drawn 
near the summit of Mount Everest have demonstrated the lowest 
recorded oxygen partial pressures in healthy subjects, with a PaO2 
range of 2.55 - 3.93 kPa.[4]
Acute high-altitude illnesses
Physiology of altitude, acclimatisation and aetiology of 
high-altitude illnesses
The complex physiological response to altitude is not yet fully 
understood and beyond the scope of this article. While the 
concentration (proportion) of oxygen in the atmosphere remains 
remarkably consistent at 20.9%, the drop in ambient pressure 
with increasing altitude results in a directly corresponding decline 
in the partial pressure (PO2). The reduction in inspired PO2 is 
compounded by the unaltered saturated vapour pressure of water in 
the alveoli, and the unaltered (or increased) metabolic production of 
carbon dioxide. Although rapid and profound compensation through 
increased minute ventilation is possible, the inevitable physiological 
consequence of ascent to high altitude is hypobaric hypoxia.[5] Over 
time, the combination of hypoxia and hyperventilation-induced 
respiratory alkalosis triggers a cascade of physiological effects, 
leading to acclimatisation. These include increased renal excretion of 
bicarbonate, a 2-3-DPG-mediated shift in the oxygen-haemoglobin 
dissociation curve, erythropoiesis, and angioneogenesis at the capil-
lary level.
Over a period of days to weeks, the body gradually adjusts to 
optimise oxygen delivery to the tissues, maintaining the oxygen 
cascade from atmosphere to mitochondrion. Indeed, given sufficient 
time to acclimatise, the human organism is remarkably capable of 
function despite low PaO2, as is eloquently demonstrated by a visit 
to any paediatric cardiology ward, where children with cyanotic 
congenital heart disease play alongside their well-oxygenated 
counterparts. However, a sudden decrease in PaO2 without adequate 
time for acclimatisation is highly likely to manifest as acute illness. In 
the context of ascent to altitude, simple respiratory compensation is 
no longer sufficient from ~3 500 m. This explains the sudden increase 
in high-altitude illnesses (HAIs) and particularly acute mountain 
sickness (AMS) seen above this point (Table 1). The exact aetiology of 
AMS, widely considered a precursor to more severe altitude illnesses, 
is also poorly understood.[6-9]
Acute mountain sickness, high-altitude cerebral 
oedema and high-altitude pulmonary oedema
Altitude illness is characterised by tissue hypoxia and oedema, 
particu larly in the brain and lungs. This is the result of a com-
plex interplay of hydrostatic pressure differences due to hypoxic 
vaso motor changes, and increased capillary permeability through 
release of agents such as vascular endothelial growth factor and 
hypoxia-inducible factor 1-alpha (HIF-1-α). The predominant 
symptom complex includes headaches, nausea and loss of appe-
tite, dizziness or lightheadedness, fatigue or weakness, and sleep 
disturbance. It is diagnosed clinically, because of the typical lack of 
advanced investigations in the context of high-altitude expeditions 
and the multifactorial nature of the disease (see ‘Clinical diagnosis’ 
below). Similarly, high-altitude pulmonary oedema (HAPE) and 
high-altitude cerebral oedema (HACE) are commonly considered 
advanced forms of AMS and diagnosed on clinical signs, but can 
and do occur independently.
Onset of altitude-related illness is indiscriminate, and can occur 
at relatively low altitudes (instances of AMS have been reported at 
as low as 2 000 - 2 500 m), but is most common after rapid ascent 
to above 3 500 m. Prior safe ascent to altitude is no guarantee of 
avoiding AMS on subsequent exposure.[8] Physical fitness, gender 
and youth are not reliably predictive, although there is a protective 
association with increased age. A genetic predisposition is being 
researched.[10-12]
Typical altitudes for onset of development of HAPE and HACE are 
3 000 m and 4 500 m, respectively. While AMS is usually diagnosed 
within a day of reaching a new elevation, HAPE and HACE 
(considered to be advanced manifestations or complications of AMS) 
commonly present after more than 24 hours at altitude.[6,13,14]
Prevention of high-altitude illness
AMS, HACE and HAPE are the most commonly encountered altitude-
induced illnesses during ascent above 2 500 m, but are also nearly 
entirely preventable.[6,7] Up to altitudes of 6 000 m, the occurrence of 
HAI is the direct result of inadequate acclimatisation. Depending on 
individual physiology and ascent profile, up to 70% of mountaineers 
develop symptoms of AMS.[14] The foremost approach to AMS, HAPE 
and HACE is prevention through education, supporting conservative 
ascent profiles to allow sufficient acclimatisation, and promoting 
adequate hydration, caloric intake and exposure protection.[3,14] 
Within the African context, AMS is very prevalent on Kilimanjaro 
owing to the lack of a sufficiently long approach trek and rapid ascent 
profiles followed by local tour operators.[15] Kilimanjaro climbs of 
<7 days’ duration are therefore considered ‘high risk’ profiles (Table 2), 
which contribute to the 3 - 8 reported but avoidable deaths out of about 
30 000 trekkers on the mountain each year.[3,13,15-19]
The single most effective method of prevention is gradual accli-
matisation, paired with adequate hydration and caloric intake. After 
reaching an elevation of 2 500 - 3 000 m, sleeping altitudes should not 
increase by more than 300 - 500 m each day, with a rest day at the 
same altitude for each 1 000 m ascent.[3,13,14] Sleeping elevation con-
tributes more significantly to adequate acclimatisation than physical 
exercise and altitude gain during the day.[13] Where terrain neces-
sitates occasional elevation gains in excess of suggested safe ascent 
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profiles, additional rest days must be incor-
porated into the itinerary to keep the aver-
age rate of ascent within safe parameters.[13] 
Adequate hydration (estimated in the field by 
maintaining frequent micturition and keep-
ing urine colourless) is imperative to allow 
the elimination of bicarbonate necessary for 
physiological acclimatisation. Although loss 
of appetite is a common feature, care should 
be taken to consume sufficient carbohy-
drate-rich meals to compensate for increased 
metabolic loads and improve the respiratory 
exchange ratio.[5] Minimising loss of body 
fat has the benefit of helping cope with low 
temperatures at high altitude; a more signifi-
cant risk of poor nutrition is subsequent loss 
of muscle mass.
Clinical diagnosis: Symptoms and 
the Lake Louise symptom score
Secondary only to proper acclimatisation, 
early recognition of AMS is key to allow-
ing individuals to take simple corrective 
measures before the risks of complications 
increase.
AMS is defined by the presence of a high-
altitude headache (onset of headache within 
24 hours of ascent to above 2 500 m) and at 
least one other symptom of sleep disorder, 
gastrointestinal upset (nausea, vomit ing or 
loss of appetite), dizziness or lightheaded-
ness, and lethargy, fatigue or weakness. 
Frequently, this is accompanied by peripheral 
oedema, shortness of breath and tachycardia, 
which often worsen at night.[8,14,20] Being 
nonspecific, these symptoms are often mis-
taken for non-consequential ailments such 
as flu, a cold or dehydration – all common 
travel complaints.[6] However, AMS should 
always be assumed until proven otherwise.[3] 
Although the diagnosis of AMS is symp-
tomatic and clinical, determining its severity 
is largely subjective. As participants focus 
on expedition goals, symptoms are often 
under-reported, which leads to an underes-
timation of severity. This can result in a lack 
of appropriate medical intervention, such 
as the climber being advised to discontinue 
an ascent. Furthermore, under-reporting of 
AMS symptoms such as severe headaches 
and drowsiness may lead to the early warn-
ing signs of HACE being missed.
To objectively standardise diagnosis and 
quantify the severity of AMS, the Lake 
Louise Symptom Questionnaire and Clinical 
Scores were established (LLSQ and LLS-C, 
respectively). This allows for both monitor-
ing of symptoms by lay mountaineers, and 
field research of AMS by expedition doctors 
(Fig. 2).[13,20,21] Each of the five symptoms and 
three clinical signs are assigned a severity-
related score from 0 (absent) to 3 (severe 
or incapacitating). Inability to stand for an 
ataxia test carries a score of 4. AMS is con-
sidered present with a score of ≥3 for the 
LLSQ, and >5 for the LLS-C. It is advisable 
that the LLSQ is performed twice daily by 
team members (in the mornings after wak-
ing, and in the evenings once settled into 
camp), and the LLS-C independently by the 
team physician.
For HAPE, AMS symptoms are typically 
aggravated by dyspnoea at rest or with 
light workloads, impaired exercise perfor-
mance, coughing, tachycardia, subjective 
chest tightness, ronchi/rales, cyanosis, mild 
fever and (in extreme cases) foamy blood-
stained sputum.[7,14,22] Importantly, HAPE 
may occur without the precedence of AMS 
symptoms.[23]
HACE commonly presents with severe 
headaches that remain unresponsive to 
analgesics, ataxia, altered level of conscious-
ness and loss of insight. A simple field test 
for ataxia is to observe an individual walking 
heel-to-toe on a straight line drawn on the 
ground.[14,24]
Complications of AMS in the form of 
HAPE or HACE may be lethal, and early 
clinical recognition is vital in austere envi-
ronments to allow suitable and effective 
treatment. Research into the use of point-of-
care ultrasound scans of the lung and optic 
nerve sheath diameter is a promising new 
modality for screening, prediction and early 
diagnosis of HAPE and HACE respectively, 
but is still at the experimental stage.[25,26]
Table 1. Consequences of acute exposure to high altitude
High altitude
(1 500 - 3 500 m)
Very high altitude
(3 500 - 5 500 m)
Extreme altitude
(5 500 - 8 850 m)
HAI occurs with rapid ascent 
above 2 500 m
Most common range for HAI 
(AMS, HAPE, HACE)
Abrupt ascent always causes 
severe HAI
↓Exercise performance
↑Ventilation
Requires acclimatisation for 
physical effort to be tolerated
Progressive physiological 
deterioration outstrips 
acclimatisation
Minor decrease in SpO2 
(usually ≥90%)
SpO2: 75 - 85% SpO2: 55 - 75%
Severe hypocarbia
PaO2: 7 - 10 kPa PaO2: 5 - 8 kPa PaO2: 3.5 - 5 kPa
Severe hypoxia unlikely in the 
absence of underlying illness 
or HAPE
Extreme hypoxia may occur 
during sleep, exercise or illness
Always requires 
acclimatisation to avoid illness
HAI = high-altitude illness; AMS = acute mountain sickness; HAPE = high-altitude pulmonary oedema; 
HACE = high-altitude cerebral oedema.
Table 2. Risk categories for AMS (Wilderness Medical Society consensus guidelines)[13]
Risk category Description
Low Individuals with no prior history of altitude illness and ascending to 
≤2 800 m
Individuals taking ≥2 days to arrive at 2 500 - 3 000 m with subsequent 
increases in sleeping elevation <500 m/day and an extra day for 
acclimatisation every 1 000 m
Moderate Individuals with a prior history of AMS and ascending to 2 500 - 2 800 m 
in 1 day
No history of AMS and ascending to >2 800 m in 1 day
All individuals ascending >500 m/day (increase in sleeping elevation) at 
altitudes >3 000 m but with an extra day for acclimatisation every 1 000 m
High Individuals with a history of AMS and ascending to >2 800 m in 1 day
All individuals with a prior history of HACE
All individuals ascending to >3 500 m in 1 day
All individuals ascending >500 m/day (increase in sleeping elevation) 
>3 000 m without extra days for acclimatisation
Very rapid ascents (e.g. <7 day ascents of Mount Kilimanjaro)
AMS = acute mountain sickness; HACE = high-altitude cerebral oedema.
Altitudes refer to the altitude at which the person sleeps; ascent is assumed to start from elevations <1 200 m; risk categories 
pertain to unacclimatised individuals. 
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Chemoprophylaxis
Although widely advised, the prophylactic 
intake of the carbonic anhydrase inhibitor 
acetazolamide (Diamox 125 - 250 mg twice 
daily) is debated in the literature.[2,13,27] By 
increasing renal bicarbonate excretion, it 
can improve the rate of acclimatisation, 
but has limited or no effect if the ascent 
profile is too rapid.[7,14,19,28] Acetazolamide 
can result in side-effects that mimic AMS 
(nausea, vomit ing, anorexia and dizziness) 
and blurred vision, severe paraesthesia and 
odd tastes in the mouth. Individuals wish-
ing to take aceta zolamide for high-risk 
ascent profiles should ideally take several 
test doses at home before the ascent. It is 
contraindicated for use in diabetes and sul-
phonamide allergy.[13,14]
Use of dexamethasone as prophylaxis (2 mg 
6-hourly or 4 mg 12-hourly) is similarly 
debated, mainly because of concerns regard-
ing masking symptoms of AMS, and its 
side-effect profile.[13,28] However, it is used 
selectively in groups making very short rapid 
high-altitude ascents, such as rescue teams.
Ibuprofen has been shown in randomised 
controlled trials to be more effective than 
placebo in decreasing the incidence of AMS, 
but this has been contested in light of the 
fact that it reduces headache, which is essen-
tial for the clinical diagnosis.[29,30] Alternative 
prophy lactic substances such as ginkgo bilo-
ba and coca-derived products have shown 
contradictory results.[13,29,31]
Individuals at elevated risk or with previ-
ous episodes of HAPE can be treated with 
nifedipine (20 mg slow-release preparation 
8-hourly) or sildenafil (20 - 50 mg 8-hourly) 
prophylactically. As both drugs can cause 
postural hypotension, a trial at home before 
departure is recommended.
Field management
For mild to moderate symptoms of AMS 
(LLSQ 3 - 5 or LLS-C >5), primary treat-
ment takes the form of rest days without any 
 
Score 0 1 2 3
Headache None Mild Moderate
Severe/ 
incapacitating
Gastrointestinal 
tract
None
Poor appetite 
or mild nausea
Nausea and/or 
vomiting
Severe/ 
incapacitating
Fatigue/ 
weakness
None Mild Moderate
Severe/ 
incapacitating
Dizziness None Mild Moderate
Severe/ 
incapacitating
Symptoms Signs
Sleep Normal
Not as good as 
usual
Woke many 
times
Unable to sleep Dyspnoea at rest
Crackles or wheezing in 
≥1 lung ﬁeld
Cough Central cyanosis
Mental status Normal
Lethargy/ 
lassitude
Disorientated/ 
confused
Diﬃcult to rouse/ 
unconscious
Weakness and/or 
↓exercise performance
Tachypnoea
None
Manoeuvres to
balance
Steps oﬀ line Falls down
Chest tightness or 
congestion
Tachycardia
Gr 1 (mild): only symptoms with 
exertion; no limitation of function
Gr 2 (moderate): ambulant, 
but limited. Rales may be present 
None One location ≥2 locations Gr 3 (serious): symptoms at rest,± confused. Rales, ↑HR ↑RR
Gr 4 (severe): comatose or 
obtunded. Frank oedema
Clinical diagnosis ( ≥2 symptoms AND ≥2 signs)
Increase in altitude above 2 500 m in last 4 days AND headache plus at least one other symptom
Symptoms + clincal score: ≥5 = AMS  
Cl
in
ic
al
Patient unable to stand for ataxia test = 4
AMS HACE
AMS with ataxia OR decreased LOC
OR 
Ataxia AND decreased LOC in absence of AMS
HAPE 
Ataxia (heel-toe)
w
ea
kn
es
s
Symptoms alone:     ≥3 = mild AMS      4 - 5 = moderate AMS       ≥6 = severe AMS
Peripheral 
oedema
Fig. 2. Diagnostic criteria for acute HAI, incorporating the Lake Louise Symptom and Clinical Scores. Graphic representation from WildMedix Mountain 
Expedition Medicine course materials, used with permission. (AMS = acute mountain sickness; HAPE = high-altitude pulmonary oedema; HACE = high-altitude 
cerebral oedema; Gr = grade; LOC = level of consciousness; HR = heart rate; RR = respiratory rate.)
 
+ ataxia or    LOC Headache 
Analgesics 
Exclude other 
causes 
+ symptoms 
AMS
Mild-moderate
(LLS 3 - 5)
Stop ascent
Analgesia
Fluids
Severe
(LLS ≥6)
Prepare descent
Analgesia
Fluids
DMZ 8 mg then 4 mg q 6 h
± ACZ 250 mg q 12 h
HACE HAPE
Prepare descent
Sit upright
Nifedipine 30 mg q 12 h
± sildenal 50 mg q 8 h
Hyperbaric chamber
Oxygen if availabe
Descend when able
Fig. 3. Flow diagram for the management of acute high-altitude illness (adapted from Davis et al.[35]). 
(AMS = acute mountain sickness; LOC = level of consciousness; DMZ = dexamethasone (first dose 
intravenously then intramuscularly); ACZ = oral acetazolamide; nifedipine = sustained-release; HAPE = 
high-altitude pulmonary oedema; HACE = high-altitude cerebral oedema; LLS = Lake Louise Score.)
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physical exertion at the current altitude, until 
all symptoms resolve[13] (Fig. 3). Additional 
supportive treatment with oral anti-emetics, 
simple analgesia, adequate hydration and 
sleeping with a slightly elevated upper body 
are effective. If symptoms do not improve 
within 24 hours, the patient should descend 
to an altitude where the symptoms are not 
present. Acetazolamide (250 mg orally twice 
daily) may be administered (particularly if 
symptoms worsen and descent is delayed).[13]
Should the presenting altitude be situated in 
a ‘terrain trap’ – a location which demands 
some ascent before descent can be com-
menced – then early descent before exacer-
bation of symptoms must be considered. 
Once symptoms have progressed further, a 
terrain trap may preclude descent, leading 
to a serious or fatal outcome. Other scena-
rios that may hamper immediate descent – 
worsen ing weather, other injuries or difficult 
terrain – deserve the same considerations.
In the presence of severe symptoms 
(LLSQ score >5), HACE should be suspect-
ed and integrated into the treatment plan.[3] 
Immediate action takes the form of refrain-
ing from any further ascent, administration 
of oxygen if available, enforced rest and 
protection against cold. Descent by any 
safe means should be initiated. Supporting 
treatment as described may be provided. 
Dexamethasone should be considered in 
severe AMS and used in all cases of HACE 
(8 mg orally every 6 hours, or 4 mg intramus-
cularly/intravenously every 4 hours).[13,14] 
As soon as the patient’s condition allows 
(able to safely navigate the terrain), descent 
must be started, going down to the altitude 
at which the patient was last completely 
well, or if that altitude is unknown, at least 
500 - 1 000 m.[6,28,32] Descent should avoid ter-
rain traps and the patient should not carry 
any loads. If descent is delayed because 
of environmental conditions, a portable 
hyperbaric chamber (PHC) is strongly 
advised.[3,14] A PHC is an inflatable, light-
weight, airtight capsule into which a patient 
is placed while the capsule is inflated by a 
foot pump to increase the internal pressure, 
simulating descent (Fig. 4). Pumping must 
be continuous to maintain air flow, making 
the use of a PHC extremely strenuous at 
high altitude. PHC treatment is to be con-
tinued for 2 - 4 hours to stabilise severely ill 
patients before descending.[24,33] PHCs are 
rare in the African context, but are carried 
by some high-altitude expeditions.
For HAPE patients, immediate rest (with 
the upper body elevated), protection against 
cold, supplementary O2, acetazolamide and 
dexamethasone followed by slow-release nife-
dipine (20 mg orally) are recommend ed. This 
can be supplemented with sildenafil (50 mg 
orally) and inhaled salbutamol or salmeterol, 
which improves pulmonary interstitial oedema 
by stimu la ting the sodium/potassium pump. 
Anti diuretics should be avoided, and use of a 
PHC should be consi der ed, if available.
All patients with severe AMS, HAPE 
or HACE should be evacuated to lower 
alti tudes, preferably by passive evacuation 
using a stretcher, beast of burden or heli-
copter. Adequate treatment equipment must 
accompany the patient during descent. The 
patient must be continuously monitored for 
deterioration, and must be safely managed 
and assisted in navigating the terrain once 
ambulant. This task should be performed 
by adequately trained and equipped medi-
cal personnel, rather than being deferred to 
guides or porters.
Re-ascent should not be considered until 
patients are completely asymptomatic after 
cessation of treatment.[13] Should it be diffi-
cult to differentiate between AMS, HAPE 
and HACE, treat for all three conditions. 
However, care must be taken in HACE to not 
inadvertently lower mean arterial pressure 
by using nifedipine, which could worsen 
cerebral oxygenation by lowering cerebral 
perfusion pressure.[8,33,34]
Scenario resolution
Faced with Mr X’s collapse on the sum-
mit ridge, you regret not speaking up at 
Mawenzi Tarn, 1 500 m below, although 
the differential diagnosis for his symptoms 
at that stage was broad, including simple 
dehydration or heat stroke. You recognise 
that the combination of headache, loss of 
appetite and poor sleep already constituted 
a clinical diagnosis of mild AMS. At Kibo, 
his breathlessness and lethargy should have 
alerted the expedition leadership that he 
should descend, or at least commence treat-
ment for AMS. In the setting of his acute 
collapse, you recognise that the differential 
includes exhaustion, hypothermia, hypo-
glycaemia, dehydration and various other 
medical conditions, but a presumptive 
diagnosis of severe AMS and high-altitude 
cerebral oedema must be made. Knowing 
that only the most rudimentary field rescue 
facilities and no helicopter are available, 
which will undoubtedly delay definitive 
medical care, you urgently administer doses 
of oral acetazolamide and intravenous dexa-
methasone as well as supplemental oxygen 
from the guide’s cylinder, and initiate a 
rapid descent. Foregoing the summit, you 
monitor his condition on an ongoing basis.
By the time Mr X reaches Kibo he is able 
to walk unaided, and you push on down 
to Horombo Huts (3 700 m). Other than 
tiredness and a slight cough, Mr X is feeling 
well. He thanks you for sacrificing your 
summit bid to assist him and affirms his 
intention to return to the mountain again 
with a more prudent acclimatisation profile.
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